Single — Molecule. Innovation.
Goal Accelerate the adoption of single-molecule techniques for drug development.
Background
Single-molecule techniques provide unparalleled insight into molecular interactions between proteins and DNA. These techniques hold tremendous promise for drug discovery by enabling high-resolution studies at the molecular level.
The Challenge
Despite their potential, single-molecule techniques face inherent throughput limitations that cannot be overcome by automation or faster analysis alone.
Removing key barriers using semiconductor technology.
Technology
The NanoLoom chip uses nanofabrication 
to arrange individual DNA molecules in a microfluidic flow cell. This design boosts measurement throughput by orders of magnitude, unlocking the true power of single-molecule imaging.
Technology
Biotech
Quality control and optimization of the molecular biology in diagnostic kits and research.
Pharma
Drug development for cancer, antibiotic resistance, dementia, and rare diseases.
Agriculture
Development of pesticides and gene-modifying agents. Development of genetic variants to increase yields.
Military
Pandemic preparedness and biosecurity.
Beyond SequencingComparable to DNA sequencing in complexity, technological challenges, and impact. While sequencing focuses on DNA mutations, NanoLoom analyses DNA-protein interactions.
NanoLoom
NanoLoom chips are compatible with most commercially available fluorescent microscopes, and liquid handling systems. With the provided reagents and our on-site user training, you can start your first experiment within hours.
Learn more
Collaborations
Partner with us to validate NanoLoom’s technology for drug discovery. Accelerate breakthroughs in novel therapies targeting DNA processing proteins, and gain early access to high throughput single-molecule solutions.
Learn more
The technique developed by 1NA, combined with fluorescence microscopy, provides high-throughput data of proteins interacting with DNA. Our group is focusing on mitochondrial dysfunctions, where this technique will be our tool of choice for screening drugs targeting the mitochondrial replication machinery.
Prof. Géraldine Farge
at Université Clermont Auvergne